[HTML][HTML] A pharmacogenetically guided acenocoumarol dosing algorithm for Chilean patients: A discovery cohort study
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - frontiersin.org
Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
[HTML][HTML] A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - researchers.unab.cl
Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study.
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - europepmc.org
Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - … Landscape of the …, 2020 - books.google.com
Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
[PDF][PDF] A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Front. Pharmacol. 11 …, 2020 - academia.edu
Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
[PDF][PDF] A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Front. Pharmacol. 11 …, 2020 - researchgate.net
Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
Á Roco, E Nieto, M Suárez, M Rojo, MP Bertoglia… - 2020 - repositorio.uchile.cl
Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
A Roco, E Nieto, M Suárez, M Rojo… - Frontiers in …, 2020 - researchers.unab.cl
Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …
events in patients with cardiovascular diseases. The most common VKA are warfarin and …